SGCB and cirrhosis of liver: In this study the effect of chronic administration of the sGC stimulator riociguat (1 mg/kg, 1 × daily, intraperitoneal) was investigated over 2–3 weeks using the models of BDL- and CCl4-induced liver cirrhosis [96].